|
10213
|
GSK HSV Vaccine
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
RNA based vaccine
|
Phase 1
|
GlaxoSmithKline
|
2021
|
UK
|
18 - 40 years
|
2 doses at interval of 2 months
|
Intramuscular
|
NA
|
Herpes simplex virus 2 glycoprotein D (gD-2)
|
mRNA based vaccine
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates
|
https://www.precisionvaccinations.com/vaccines/hsv-2-vaccine-gsk4108771a#:~:text=The%20herpes%20simplex%20virus%20type,genetic%20code%20of%20a%20virus.
|
|
10297
|
HSV15
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
Subunit vaccine
|
Phase 2
|
Sanofi Pasteur
|
2021
|
USA
|
18 - 55 years
|
NA
|
Intramuscular
|
NA
|
Wild-type HSV virus components except two proteins UL5 and UL29
|
NA
|
US FDA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
NA
|
NCT04222985
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates
|
https://clinicaltrials.gov/ct2/show/NCT04222985
|
|
10371
|
Simplirix
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
Subunit vaccine
|
Phase 3
|
GlaxoSmithKline
|
2008
|
UK
|
18 - 30 years
|
NA
|
Intraperitoneal
|
3-deacylated form of MPL, alum
|
Herpes simplex virus 2 glycoprotein D (gD-2)
|
NA
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
NA
|
NCT00057330
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates, https://clinicaltrials.gov/ct2/show/NCT00057330
|
NA
|
|
10381
|
Delta gD-2
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
Subunit vaccine
|
Preclinical
|
X-Vax Technology Inc.
|
NA
|
USA
|
NA
|
NA
|
Intramuscular
|
NA
|
Herpes simplex virus 2 glycoprotein D (gD-2)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates
|
https://www.frontiersin.org/articles/10.3389/fmicb.2021.798927/full
|
|
10382
|
EXD-12
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
Live-attenuated
|
Preclinical
|
Excell Biotech
|
2018
|
USA
|
14 - 49 years
|
NA
|
NA
|
NA
|
Herpes simplex virus 2 glycoprotein D (gD-2)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates
|
NA
|
|
10383
|
NanoVax
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
Subunit vaccine
|
Preclinical
|
BlueWillow Biologics
|
NA
|
USA
|
NA
|
NA
|
Intranasal
|
NA
|
Herpes simplex virus 2 glycoprotein D (gD-2)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates
|
NA
|
|
10384
|
RVx201
|
Genital Herpes
|
Cutaneous
|
Herpes simplex virus
|
double stranded DNA
|
Live-attenuated
|
Preclinical
|
Rational Vaccines Inc.
|
2021
|
UK
|
NA
|
NA
|
NA
|
NA
|
HSV-2 infected cell protein
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates
|
NA
|